NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Recent movement. (Update)

1. Combination patent application in Europe to be granted, includes both DCVax-l (lysate pulsed) and/or DCVax-Direct (partial maturation) with checkpoint inhibitors.
2. 72 days since MAA was filed.
3. MHRA and FDA looking at further cooperation.
4. Nature Journal article on DC/poly-iclc combination study nearing publication. Primary completion date for study occurred nearly thirty days ago.
5. Active negotiations with other parties for combination trials going on for over a year, awaiting MAA to be “cemented.”
6. Large pharma struggling to adapt to upcoming patent cliffs.
7. Cohen/Milstein/Posner about to file second amended complaint, and with it, formulaic method to arrive at loss causation.
8. Flaskworks (aka: NWBO) continues IP momentum.
9. Advent hiring head of production to hire team to facilitate biotherapeutic production for clinical use. (Direct?)
10. FDA pursuing Promising Pathways.
11. Apparently NICE has been working with NWBO recently, and it anticipates an update on the topic website in the next week or so.
12. The End Brain Cancer Initiative (EBCI) Advocates for DCVax®-L to Gain FDA Approval
13. 10 Minute Rule Bill passed in UK for the 3,200 people who are diagnosed with a glioblastoma brain tumour every single year